Delaying diabetes by years
Since the discovery of insulin in 1922, no drug has been able to alter the course of Type 1 diabetes — until recently. Now the medication teplizumab delays onset of the condition by an average of two years — and sometimes by more than a decade, says Kevan Herold, MD, a principal investigator of the drug and an immunologist at Yale Medicine in New Haven, Connecticut. That’s a significant development given that 30,000 U.S. patients are diagnosed with the autoimmune condition each year.
View Report